Qualigen Therapeutics Inc
For the period ended Dec 31, 2023. Filed Apr 8, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Apr 8, 2024
FFR$0.91+1.9%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
| December 31, | December 31, | |
|---|---|---|
| 2023 | 2022 | |
| ASSETS | ||
| Current assets | ||
| Cash | $401,803 | $3,165,985 |
| Prepaid expenses and other current assets | 764,964 | 1,366,704 |
| Current assets of discontinued operations | — | 6,287,849 |
| Total current assets | 1,166,767 | 10,820,538 |
| Property and equipment, net | — | 26,242 |
| Other assets | 866,481 | — |
| Non-current assets of discontinued operations | — | 8,236,711 |
| Total Assets | $2,033,248 | $19,083,491 |
| LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT) | ||
| Current liabilities | ||
| Accounts payable | $2,222,983 | $619,568 |
| Accrued expenses and other current liabilities | 560,006 | 864,559 |
| Warrant liabilities | 54,600 | 788,100 |
| Warrant liabilities - related party | — | 2,834,547 |
| Convertible debt - related party | 1,299,216 | 60,197 |
| Current liabilities of discontinued operations | — | 3,441,198 |
| Total current liabilities | 4,136,805 | 8,608,169 |
| Non-current liabilities of discontinued operations | — | 1,708,732 |
| Total liabilities | 4,136,805 | 10,316,901 |
| Commitments and Contingencies (Note 10) | - | - |
| Stockholders’ equity (deficit) | ||
| Qualigen Therapeutics, Inc. stockholders’ equity (deficit): | ||
| Common stock, $0.001 par value; 225,000,000 shares authorized; 5,362,128 and 4,210,737 shares issued and outstanding as of December 31, 2023 and December 31, 2022, respectively | 43,262 | 42,110 |
| Additional paid-in capital | 114,655,565 | 110,528,050 |
| Accumulated other comprehensive income | — | 50,721 |
| Accumulated deficit | (116,802,384) | (103,385,172) |
| Total Qualigen Therapeutics, Inc. stockholders’ equity (deficit) | (2,103,557) | 7,235,709 |
| Noncontrolling interest | — | 1,530,881 |
| Total Stockholders’ Equity (deficit) | (2,103,557) | 8,766,590 |
| Total Liabilities & Stockholders’ Equity (Deficit) | $2,033,248 | $19,083,491 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.